EFFICACY OF MIDOSTAURINE IN ACUTE MYELOID LEUKEMIA WITH FLT-3 MUTATION

Egamova Sitora Kabilovna

doi:10.17605/OSF.IO/DPZGA

EFFICACY OF MIDOSTAURINE IN ACUTE MYELOID LEUKEMIA WITH FLT-3 MUTATION

Authors

Egamova Sitora Kabilovna Bukhara State Medical Institute Bukhara, Uzbekistan

DOI:

https://doi.org/10.17605/OSF.IO/DPZGA

Keywords:

acute myeloid leukemia, mutation, midostaurin

Abstract

Detection of FLT3-ITD mutation in patients with acute myeloid leukemia (AML) is associated with a poor prognosis and is an indication to transplantation of allogeneic hematopoietic stem cells in the first remission. Midostaurin is the first FLT3 inhibitor approved ny for the treatment of patients with AML with FLT3 mutation.

Downloads

Published

2022-09-18

How to Cite

Egamova Sitora Kabilovna. (2022). EFFICACY OF MIDOSTAURINE IN ACUTE MYELOID LEUKEMIA WITH FLT-3 MUTATION. Open Access Repository, 9(9), 9–11. https://doi.org/10.17605/OSF.IO/DPZGA